Gender is an important feature in the management of atrial fibrillation (AF). This study investigated gender-related differences in patients with AF in Turkey. Methods: As a part of RAMSES (ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in Turkey, NCT02344901) study, information of the patients with AF who successively applied to the hospital was analyzed. This cross-sectional, multicenter, nationwide observational study enrolled 6264 non-valvular AF (NVAF) outpatients (55.9% women) from Turkey. 
A trial fibrillation (AF) is the most common sustained cardiac rhythm disorder [1] and is associated with high risk of stroke, heart failure, impaired cognitive function, and poor quality of life. [2, 3] Recent European and American guidelines recommend the CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age [>75 years], diabetes, stroke/transient ischemic attack, vascular disease, age [65-74 years], sex category [female]) for thromboembolic risk stratification of patients with non-valvular AF (NVAF), which includes female sex as a risk factor. [4, 5] Women have a longer life expectancy than men; therefore, they constitute a larger proportion of the elderly population who are at risk of complications caused by AF. [6] Previous studies have revealed that among patients with AF, women tend to be at higher risk for stroke than men, [6, 7] even after adjustment for baseline comorbid conditions and vitamin K antagonist (VKA) treatment. [8] [9] [10] However, they are under-represented in mixed-sex cardiovascular trials, resulting in a deficit of information on differences in treatment effect and in side-effect profiles. [11] In the Euro Heart survey report from 2007, Dagres et al. reported that compared with males, female patients were older, had a lower quality of life, and had more comorbidities, but prescription of oral anticoagulants (OAC) was identical in both genders. [12] In an analysis from the dataset of the Euro Observational Research Programme on Atrial Fibrillation (EORP-AF) pilot survey, Lip et al. examined sex-related differences in presentation, treatment, and outcome of contemporary patients with AF in Europe. [13] They found that female subjects were older and more symptomatic, had more heart failure with preserved ejection fraction, were offered less rhythm control, and OACs were used in a higher proportion (95.3% of females vs 76.2% of males). [13] However, most data on epidemiology and management of AF come from Europe and the United States. In Turkey, there are no data available about genderrelated differences in presentation, management, or outcomes among AF patients. In this analysis of the baseline dataset of the Real-life Multicenter Survey Evaluating Stroke Prevention Strategies in Turkey (RAMSES) study, sex-related differences in presentation and treatment of contemporary patients with NVAF in Turkey were examined.
METHODS
The RAMSES study was a cross-sectional, multicenter, nationwide observational study conducted with NVAF patients in Turkey (ClinicalTrials.gov identifier NCT02344901). Presently described is study of clinical data of the RAMSES study patients. Design and rationale of RAMSES trial have been described in detail elsewhere. [14] In brief, the RAMSES registry population comprised consecutive outpatients with NVAF presenting to cardiologists in participating Turkish cities, and all data were collected in a single visit. To ensure inclusion of adequate geographic diversity, number of patients proportionate to the total population of every region were enrolled. State, university, education and research, and private hospitals were included in order to represent all patients treated within different health care settings. The study was initiated in February 2015 and the last patient was enrolled in May 2015. Patients were officially enrolled in the RAMSES study only if an electrocardiogram (ECG) diagnosis (12-lead ECG, or other electrocardiographic documentation) confirming AF was made.
Although definition of NVAF is controversial, valvular AF is defined as AF related to rheumatic valvular disease (predominantly mitral stenosis), or prosthetic heart valve in the RAMSES study. The RAMSES trial excluded patients with mitral stenosis, or mechanical prosthetic heart valve. Patient characteristics and demographics, including geographical diversity, and OAC use (including non-VKA oral anticoagulants [NOACs] and VKAs) were recorded. Guideline-based use of anticoagulation in eligible patients and reasons for not using OAC therapy were analyzed. Primary aim of the RAMSES study was to evaluate appropriateness of stroke prevention strategies applied for patients with NVAF. Secondary goals were to find time in therapeutic range (TTR) for patients taking warfarin, CHA 2 Major bleeding was defined according to International Society on Thrombosis and Haemostasis criteria: [15] Fatal bleeding and/or symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a drop in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells. Minor bleeding is defined as non-major bleeding. The present study was approved by the local ethics committee.
Statistical analysis
Continuous variables were summarized as median with interquartile ranges, and categorical variables were expressed as frequencies and percentages. Mann-Whitney U test was used to compare continuous variables and chi-square test was applied for categorical variables. Normality of continuous variables was tested by Kolmogorov-Smirnov test. All analyses were performed using SPSS software, version 21.0 (IBM Corp., Armonk, NY, USA). P value of <0.05 was considered significant.
RESULTS
Study population A total of 6273 patients with NVAF were enrolled from 29 provinces and 57 hospitals of Turkey. After excluding 9 patients whose medical history could not be determined, data of 6264 patients were evaluated in the present study. Median age of the patients was 70 years (range: 63-77 years) and 3503 (55.9%) were women. Nearly half of the patients (45.1%) were recruited in tertiary hospitals, 43.6%
were recruited in state hospitals, and 11.3% were recruited in private hospitals. Most common comorbid condition was hypertension (68.7%), and one-fifth of the patients had at least 1 comorbid disease. Median CHA 2 DS 2 -VASc score was 3 (range: 2-4) and HAS-BLED score was 2 [range: [1] [2] . Overall OAC use was 58.3% (30.9% NOAC, 27.4% VKA), while 18.7% of the patients were prescribed only antiplatelet drugs without any OAC therapy.
Comparison of baseline characteristics in men and women
Baseline characteristics of the cohort according to sex are shown in Table 1 • Antiplatelet drugs, including aspirin, adenosine diphosphate receptor inhibitors, and P2Y12 inhibitors were less frequently prescribed for women (27.9% vs 37.8%; p<0.001).
• Twenty-one percent of men and 17.5% of women received an antiplatelet alone, and 9.3% of men and 8.2% of women received no antithrombotic therapy.
prescribed calcium channel blocker drugs less often than women (20% vs 26.6%; p<0.001). Antithrombotic therapy use was also different in men and women:
• Anticoagulant therapy was prescribed for 74.5% of female patients. Of these, 34.7% were prescribed VKA. Remaining 39.8% were prescribed NOAC; 19.1% received dabigatran, 20.7% received Factor Xa inhibitor.
• Anticoagulant therapy was prescribed for 69.9% of male patients. Of these, 35.2% were prescribed VKA. Remaining 34.7% were prescribed NOAC; 17.6% received dabigatran, 17.1% received Factor Xa inhibitor. 
Antithrombotic therapy use in men and women according to bleeding risk score
Use of antithrombotic drugs according to bleeding risk stratum is shown in Figure 2 . Patterns of anti- (Table 3 ). Other reasons given by cardiologists for not prescribing anticoagulant drugs to these patients were first AF episode in 6 female patients (0.7%) and 5 male (1.0%); patient preference in 83 females (10.0%) and 61 males (11.2%), history of bleeding in 10 female (1.2%) and 9 male (1.6%), high risk of fall in 38 female (4.6%) and 41males (7.4%), and physician neglect in 3 female (0.4%) and 1 male (0.2%) patients (Table 3) .
DISCUSSION
In this nationwide analysis, sex differences in clinical features and management of NVAF patients as managed by Turkish cardiologists participating in the RAMSES registry are reported.
thrombotic use were analyzed for men and women, in both low-risk (HAS-BLED score: 0-2) and high-risk (HAS-BLED score: ≥3) groups.
Overall rate of use of anticoagulants was higher in patients at low risk of bleeding (70.7% of men and 76.1% of women; p<0.001) when compared with those at high risk (66.1% of men and 67.4% of women; p=0.612).
Both men and women at high risk of bleeding were more likely than those at low risk to receive combination antithrombotic therapy or antiplatelet therapy alone.
Main reasons for undertreatment in patients for whom anticoagulation is indicated
Primary reason for not giving anticoagulant to patients at moderate to high risk of stroke (CHA 2 DS 2 Turkish female patients. [24] Our study also indicated that female patients were older and more frequently had hypertension, chronic renal disease, and diabetes. However, male patients more frequently had coronary artery disease and congestive heart failure. These findings are consistent with previous reports. [26, 27] As expected, women in our study had higher CHA 2 DS 2 -VASc score, given the nature of this score and older age of the women. Although women with AF have more symptoms than men, and female gender is a well-recognized, independent risk factor for AF-related stroke and systemic thromboembolism, [28] previous studies have demonstrated that treatment is more conservative in women, with significantly less utilization of rhythm-control strategies, electrocardioversion, beta-blockers and OACs. [29] The Canadian Registry of Atrial Fibrillation (CARAF) study found that women were half as likely to receive warfarin and twice as likely to receive aspirin, compared with men.
[30] However, contemporary global data indicate that anticoagulant use for stroke prevention is no different in men and women with NVAF, but remains suboptimal in both sexes. [31] There are no specially designed studies regarding appropriateness and guideline adherence of anticoagulant therapy in Turkey, either in general or for individual sex. The RAMSES study has documented greater use of anticoagulant in women with NVAF in Turkey (74.5% of female patients, 69.9% of male patients were prescribed OACs). However, present study has also shown that anticoagulant drugs were underprescribed in high-risk patients and overprescribed in low-risk patients in both sexes. In contrast to literature data, our study results indicated that women with NVAF tend to have lower rates of undertreatment compared with men. Although not statistically significant, overtreatment rates were also lower for female patients with NVAF than for men.
These results indicate that suboptimal thromboprophylaxis with underuse in moderate-to high-risk patients, and overuse in low-risk patients despite recent introduction of NOACs, are of concern and indicate need for improved stroke prevention in cases of AF.
When women are prescribed systemic anticoagulation, differences may also exist in terms of quality of anticoagulation. According to the Atrial Fibrillation Follow-up Investigation of Rhythm Management
Our results indicate that women with NVAF were older, had more comorbid diseases, and were at higher stroke risk overall (although prior stroke history was similar to that of men). Compared with men, OAC therapy use was higher in women. Quality of anticoagulation, as measured by TTR for patients receiving warfarin therapy, was similar for men and women. Although overtreatment rates were similar, undertreatment rates were lower in women compared with men.
AF is the most common arrhythmia, worldwide. Although estimated prevalence is lower in women (373 per 100,000) than in men (596 per 100,000), [16] true prevalence is likely to be substantially higher, especially in women, given that many individuals remain undiagnosed. In North American and European populations, age-adjusted incidence of AF has been estimated to be 2-fold higher in men than in women. A Minnesota study reported AF incidence (per 1,000 person-years) in women to be 2.7, compared with 4.7 in men. [17] Similar to incidence, age-adjusted prevalence of AF has been reported to be lower in women. A large, retrospective study of older adult (aged ≥65 years) US Medicare recipients reported prevalence of AF to be 7.4% in women and 10.3% in men. [18] However, prevalence studies of Asian populations have been less consistent than those of North American and European poulations. Li et al. reported that ageadjusted prevalence of AF was similar in women and men in Chinese population. [19] Moreover, in North American populations, despite higher incidence of AF in men, lifetime risks of AF in women and men were similar, due to longer life expectancy for women. [20] Our study demonstrated that 55.9% of NVAF patients were female. In Turkey, we do not have sufficiently broad studies to ascertain prevalence rates of AF in the population. Only a small number of studies have been performed and published within the past few years, and most of them have retrospective or observational design. [21] [22] [23] [24] [25] The Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study was the largest of these studies, which enrolled 2242 consecutive patients with AF. [25] Similar to our findings, the AFTER study showed that female patients made up 60% of study population. The RAMSES and AFTER studies enrolled more female patients than male patients, unlike most other studies, which primarily enrolled male patients. This may be due to higher incidence of AF in in the RAMSES study. Female subjects were older and had higher risk for stroke compared with males. Compared with men, women with NVAF had higher prescription of OACs, had similar quality of anticoagulation, and had lower over-and undertreatment rates. However, analysis of anticoagulation therapy showed that 61.6% of women with CHA 2 DS 2 -VASc score of 1 and 68.5% of men with CHA 2 DS 2 -VASc score of 0 received anticoagulation therapy, which is not indicated in such patients, according to the guidelines. Moreover, although clearly indicated, 30.5% of men, and 25.3% of women with high risk for stroke (CHA 2 DS 2 -VASc score: ≥1 [male], ≥2 [female]) had not received any anticogulant therapy. Our data suggest that women with NVAF are receiving better treatment than men, but adherence to anticoagulation guidelines is poor in practice and may be modestly improved with NOACs. Therefore, it seems essential to design and conduct longitudinal studies evaluating prevalance, management, and prognosis of AF in both sexes throughout the country.
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(AFFIRM) study, women with AF on warfarin spent less time in TTR than men. [32] However, TTR values of females were not different from those of males, which indicates similar quality of anticoagulation in warfarin prescribed to women.
In our cohort, women were more likely to be prescribed a NOAC. Recent studies demonstrate that women may have improved outcomes with NOAC compared to warfarin therapy. [33] A recent meta-analysis that included 5 randomized control trials with gender data on warfarin and on NOACs, found improved reduction in rate of ischemic stroke and reduced major bleeding with NOACs compared with warfarin therapy in women. [33] However, prospective real-world studies evaluating impact of NOACs in reducing stroke risk in women are needed.
Although pharmacotherapy of AF has improved over time, guidelines are different regarding management of AF in women and men. The 2012 European Society of Cardiology guidelines recommend OAC therapy for male patients with CHA 2 DS 2 -VASc score of ≥1 and for female patients with a score of ≥2, [4] whereas the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines recommend use of OAC at CHA 2 DS 2 -VASc score ≥2 for patients of both sexes. [5] Further sudies are needed to determine significance of gender differences in the management of AF in our country.
Limitations
The present study is a post-hoc analysis, and therefore is not designed to determine gender differences in outcome. However, it provides useful, real-life data regarding NVAF patients seen in daily clinical practice. Study was conducted in outpatient cardiology clinics, and this may have limited coverage of all NVAF patients; however, participating institutions were geographically widely distributed across Turkey, both smaller and major cities of Turkey were represented, according to population.
Conclusion
To the best of our knowledge, our study cohort represents by far the largest number of patients with AF in Turkey. The present study provides contemporary data on sex differences in clinical features and management of AF patients who participated
